Alan D. Frazier
Frazier Healthcare Ventures Managing Partner @ Frazier Technology Ventures
Bremerton, United States
Alan D. Frazier is a Series A investor at Frazier Technology Ventures in Bremerton focused on Health Care and Biotechnology. Mr. Frazier is the founder and managing partner of Frazier Healthcare. Mr. Frazier assists with evaluating Growth Equity and Biopharma Venture investments. He has been integrally involved in growing several successful early-stage life science companies into national prominence, including Immunex, Affymax and Affymetrix. Mr. Frazier has led severalsuccessful investments for the firm such as Tularik and CV Therapeutic. Recently he has led the development of successful growth equity companies such as TridentUSA Health Services.Currently Mr. Frazier serves on the boards of Abode Healthcare, Cadence Pharmaceuticals (NASDAQ: CADX), Packaging Coordinators, and TridentUSA Health Services. Prior to forming Frazier Healthcare, Mr. Frazier was the Executive Vice President and Chief Financial Officer of Immunex Corporation. Later, he served as the Senior Financial Advisor and Chief Financial Officer of Affymax and worked on the spinout of Affymetrix. Prior to Immunex, Mr. Frazier was head of the Emerging Business Practice and co-head of the Technology Practice for the Seattle office of Arthur Young Company (now, Ernst & Young). Mr. Frazier holds a B.A. in Economics from the University of Washington.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Alan D. Frazier invests in
Stages Alan D. Frazier invests in
Countries Alan D. Frazier invests in
Investment Focus
Industry
- Health Care 3 (50%)
- Biotechnology 2 (33%)
- Medical 1 (17%)
- Computer 1 (17%)
- Hospital 1 (17%)
Stage
- Series A 3 (50%)
- Series B 1 (17%)
- Series D 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Proprio
|
Proprio is a Seattle-based company utilizing machine learning, automated intelligence, and mixed-reality user interfaces to develop a next-generation surgical navigation and imaging platform to improve surgical accuracy, simplify surgical workflows, and improve patient outcomes.The solution they’re building supplants surgical microscopes,navigation systems, loupes, and screens, replacing surgical microscopes alone wouldn’t be a compelling enough goal for them though.Their greater vision is to move medicine out of the past and into a future that fully leverages not only existing technologies, like AR/VR but one where medical innovation can move at the pace of software development in other industries. In order to realize that future, they have to move away from a dependency on ground glass, in the case of microscopes, and toward a focus on software and data, and leverage the emerging capabilities of computer vision and machine learning to enhance the combined performance of humans and computers. | $23M / Series A / Jun 17, 2020 | |
CI Security
|
CI Security is a security company that provides managed cyber-security solutions. The company is an information security platform providing managed detection and response services to help you be secure, compliant, and resilient against threats to the life safety, life-sustaining, and quality-of-life systems and services you provide to clients,customers, constituents, and communities. It focused on protecting and defending critical services in healthcare, the public sector, and the businesses that support them.The Critical Insight (CI) solution combines next-generation processing with an expert human touch to deliver advanced Managed Detection and Response (MDR), integrating cleanly into your existing strategy. CI Security was founded in 2012 and is headquartered in Seattle, Washington, United States. | $1.1M / Series A / Jan 04, 2018 | |
|
CI Security
|
CI Security is a security company that provides managed cyber-security solutions. The company is an information security platform providing managed detection and response services to help you be secure, compliant, and resilient against threats to the life safety, life-sustaining, and quality-of-life systems and services you provide to clients,customers, constituents, and communities. It focused on protecting and defending critical services in healthcare, the public sector, and the businesses that support them.The Critical Insight (CI) solution combines next-generation processing with an expert human touch to deliver advanced Managed Detection and Response (MDR), integrating cleanly into your existing strategy. CI Security was founded in 2012 and is headquartered in Seattle, Washington, United States. | $3.3M / Series A / Apr 05, 2017 | |
Alexza Pharmaceuticals
|
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. It was founded in 2001 and headquartered in Mountain View, California. | $52M / Series D / Jan 06, 2005 | |
|
Alexza Pharmaceuticals
|
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. It was founded in 2001 and headquartered in Mountain View, California. | $45M / Series A / Sep 25, 2002 | |
Nuon Therapeutics
|
Nuon Therapeutics is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain. | Series B |
Co-Investors
About Frazier Technology Ventures
Venture capital firm focused on investments in the northwest.
Frazier Technology Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alan D. Frazier
Frazier Healthcare Ventures Managing Partner
|
|||
Gary Gigot
General Partner
|
|||
Thomas Hodge
Senior Advisor
|
|||
2 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alan D. Frazier invest in?
Alan D. Frazier invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alan D. Frazier last invest?
The most recent investment recorded for Alan D. Frazier closed in Jun 2020. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
